A Open-label, 52 Week, Extension to an 8-week, Double Blind, Multicenter, 6-arm, Placebo-controlled, Parallel Group Study to Evaluate the Long Term Safety of SPA100 (Aliskiren/Amlodipine)
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Aliskiren/amlodipine (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Novartis
- 19 Aug 2016 New trial record
- 20 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI101347)
- 22 Mar 2012 Status changed from active, no longer recruiting to completed.